Inhibiting miR-155 expression in noninfectious challenges such as stroke, brain trauma, and experimental autoimmune encephalitis decreases brain inflammation, possibly via SOCS1 and SHIP-1 [55–57]. Here, INPP5D is linked to inflammatory response.